Amarin Corp Plc (AMRN)

[HDGabor]

c-

1. The price of AMRN will be negotiated country by country, and the efficacy of the drug is taken into consideration.

Yes … as:
- negotiated with the governments or a non-governmental agency
- the price will be negotiated / determined first
- the co-pay will be determined based on the type of the treatment and the efficacy of the drug

2. Vascepa will have 11 years without any other branded drug or generic drug competition. Thus the price may start out at a higher price than what Vascepa receives in the US in that it had to be priced lower because it was competing against a generic Lovaza before R-I results were known.

a.) V has 10 years. The 11th will be given if a new indication will be approved.
b.) the price will be a result of the negotiation … and all governments are using external and / or internal pricing reference system
c.) meanwhile the price could be high (determined by "Amarin") without an agreement with the governments (e.g. in Germany, during the first 12 months) the co-pay will be 100% in this case.

3. Vascepa in Europe is unique. It will not only be the only Omega-3 approved for reimbursement but will be labeled for Cardiovascular Disease.

a.) Meanwhile Lovaza / Omacor recommendation for Cardiovascular Disease was withdrawn, it was not banned, still approved for reimbursement or is an OTC drug.
b.) Meanwhile Vascepa will be the only Omega-3 labeled for Cardiovascular Disease … it will not be the only drug labeled for Cardiovascular Disease …

4. When Vascepa is launched in Europe, most likely in Germany, I believe it will be priced to produce around $2000 per year, per patient. If it were priced to produce only $600 per year that would be only $50 per month...that number seems way too low for a branded drug with no competition.

The same or higher price is not likely … Average drug price in Germany lower by 51% compared to US. (e.g.: Ibrance US price is $13,000 / month … German price was $6,200 / month before negotiation / agreement … settled: $3,250 / month.)
But let's assume "it will be priced to produce around $2000 per year, per patient." …. Amarin licensing revenue will not exceed 30% … $600 per year (Please note: I replied to "AMRN … would be able to receive $2000 per patient in revenues").

Worth a read:

A Painful Pill to Swallow: U.S. vs. International Prescription Drug Prices

MEDICINES REIMBURSEMENT POLICIES IN EUROPE

Pharmaceutical Pricing in Europe

Best,
G